Last updated on September 2017

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors


Brief description of study

This is an open-label, multicenter, single-arm, two-stage, Phase Ib study designed to assess the safety, tolerability, and pharmacokinetics of oral cobimetinib with intravenous (IV) atezolizumab and bevacizumab in participants with metastatic colorectal cancer (mCRC) who have received and progressed on at least one prior line of therapy that contained a fluoropyrimidine and oxaliplatin or irinotecan. There are two stages in this study: Stage 1 (safety run-in phase) and Stage 2 (dose expansion phase with two cohorts, an expansion cohort and a biopsy cohort).

Clinical Study Identifier: NCT02876224

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Reference Study ID Number: CO39083 ...

University Of Colorado
Aurora, CO United States
  Connect »

Reference Study ID Number: CO39083 ...

Dana-Farber Cancer Institute
Boston, MA United States
  Connect »

Reference Study ID Number: CO39083 ...

Memorial Sloan-Kettering Cancer Center
New York, NY United States
  Connect »

Reference Study ID Number: CO39083 ...

Duke Clinical Research Institute
Durham, NC United States
  Connect »

Reference Study ID Number: CO39083 ...

Sarah Cannon Research Inst.
Nashville, TN United States
  Connect »

Reference Study ID Number: CO39083 ...

The University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Reference Study ID Number: CO39083 ...

Hospital Universitario Vall d'Hebron
Barcelona, Spain
  Connect »

Reference Study ID Number: CO39083 ...

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
Madrid, Spain
  Connect »

Reference Study ID Number: CO39083 ...

HCA Healthcare
London, United Kingdom
  Connect »